Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 12:08 PM
Ignite Modification Date:
2025-12-24 @ 12:08 PM
NCT ID:
NCT01125761
Eligibility Criteria:
Inclusion Criteria:
* Patients who sign the Deed of Consent (IC) in two ways, by his own free will, agreeing with all study procedures;
* Patients older than 18 years, any ethnicity, class or social group, regardless of sex;
* Patients with pictures of dermatoses acute, subacute or chronic, of inflammatory origin and / or allergic, to which it is recommended the use of drugs under investigation topically, such as:
* atopic dermatitis,
* prurigo,
* primary contact dermatitis or allergic
* urticaria,
* pharmacodermic,
* allergic vasculitis,
* dyshidrosis,
Exclusion Criteria:
* Patients being treated with antibiotics;
* Participation in clinical trials in the 12 months preceding the survey;
* Current treatment with immunosuppressants (eg, cyclosporine or methotrexate);
* Current treatment with phototherapy (UVA, UVB, PUVA and lasers);
* Use of systemic corticosteroids at inclusion visit or within 15 days prior to inclusion;
* Topical treatments at the site of acne in the 15 days preceding the visit of inclusion;
* Presence of any skin condition in areas affected by acne that hamper the evolutionary analysis of the lesion;
* Presence of secondary infections at the site of treatment, diagnosed clinically;
* Presence of other eczematous picture, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome Wiskott-Aldrich;
* Pregnant or lactating women;
* Chronic alcoholism;
* Patients with a history of hypersensitivity to any component of the formulas of the products under investigation;
* Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study;
* Allergic Dermatosis of moderate or severe that, according to the investigator, is not justified topical.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01125761
Study Brief:
Protocol Section:
NCT01125761